Drug intelligence / Profile preview

Wemycin

Development stage: Unknown
Lead developer: Merlin Pharmaceuticals
Modality: Small Molecules
Administration: Intravenous, Intramuscular

Overview

Wemycin is an injectable antibiotic product manufactured by Merlin Pharmaceuticals. It contains gentamicin sulphate, a small molecule aminoglycoside, as its active ingredient. Wemycin exerts its antibacterial effect by binding to the 30S subunit of the bacterial ribosome, which leads to the interruption of protein synthesis and subsequent bacterial cell death. It is primarily used to treat serious infections caused by Gram-negative bacteria. Due to poor oral absorption and hepatic inactivation, the drug is administered via intravenous or intramuscular injection.

Brand names: Wemycin
Other names: Wemycin Injection

Targets

Bacterial Ribosome

Beyond the preview

Go deeper on Wemycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wemycin.

Explore the full profile